Metabolic Changes in Chronic Hepatitis C Virus Patients Receiving Direct Acting Antivirals
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Change from baseline Glycosylated Hemoglobin within 6 months
研究概览
简要总结
Observational Study to check metabolic changes between two different hepatitis C antiviral medication groups. This study will evaluate the impact of different treatments on Serum lipid changes, fasting blood glucose and glycated hemoglobin . It will determine if changes are due to different Antiviral regimens or due to different Sustained virological response rates.
详细描述
The aim of this study is;
- To investigate and compare the changes in the total lipid profile and glycated hemoglobin (HbA1c) for chronic hepatitis C patients after receiving either one of two different direct antiviral regimens: sofosbuvir/daclatasvir and sofosbuvir/ledipasvir (Harvoni).
- To evaluate the impact of treatment response on the serial changes of serum lipid levels and glycated hemoglobin after receiving either of the two different direct antiviral regimens.
- To determine whether the change in the lipid profile and HbA1C is due to different antiviral regimens or due to different SVR rates.
Recruitment will be based on reviewing newly admitted patients and choosing those who are treatment naive and easy to treat according to study inclusion criteria. Thorough check of patient file will be done before starting the study. Eligible patients will sign a consent before starting both the treatment and the study. Patients will be divided into two groups taking treatment for 12 weeks. After treatment, patients will be followed-up for up to 12 weeks.
Patients will be asked to fast for a total of 12 hours. First 8 hours of fasting, a blood sample will be withdrawn for fasting blood sugar and glycated hemoglobin. At 12 hours of fasting, another sample will be withdrawn for lipid profile.
At baseline, patients dermographics (sex, age, weight, height, BMI), full medication history and full medical history will be collected from both patient file and patient consultation. After end of treatment at week 24, weight will be measured and BMI will be also be calculated. Adverse effects reporting:Patients will be asked about any undesirable effects detected throughout the trial which would be reported.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients age 18 to 75 years old. Patients ≥ 65 years old should undergo cardiological assessment prior to therapy by ECG, echocardiography and cardiological consultaion.
- •Easy to treat group: treatment naïve patients with serum HCV RNA positivity by PCR.
- •Clinically stable condition.
- •Platelet count ≥ 150,000/mm³.
- •INR ≤ 1.2
- •Serum albumin ≥ 3.5 g/dl.
- •Total serum bilirubin ≤ 1.2 mg/dl.
- •eGFR > 30 ml/min
排除标准
- •Pregnancy or inability to use effective contraceptives.
- •Inadequately controlled diabetes mellitus (HbA1c > 9%)
- •HCV-HIV co infection.
- •HBV-HCV co infection.
- •Any cause for chronic liver disease other than hepatitis C
- •Hyper or hypothyroidism.
- •Hepatocellular carcinoma, except 6 months after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI)
- •Extra-hepatic malignancy except after two years of disease-free interval.
- •Fibrosis: FIB-4 index ≥ 3
- •Patients prescribed with lipid-lowering agents (statins).
研究组 & 干预措施
sofosbuvir plus daclatasvir
50 patients receiving 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
干预措施: sofosbuvir plus daclatasvir (Drug)
sofosbuvir plus ledipasvir
50 patients receiving 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
干预措施: Sofosbuvir plus Ledipasvir (Drug)
结局指标
主要结局
Change from baseline Glycosylated Hemoglobin within 6 months
时间窗: baseline, week 4 (during treatment), week 24 (after end of treatment)
average level of blood sugar over the past 2 to 3 months, measured in percentage %
Change from baseline Fasting Blood Glucose within 6 months
时间窗: baseline, week 4 (during treatment), week 24 (after end of treatment)
measured as mg/DL after 8 hours of fasting
Change from baseline Total Lipid Profile within 6 months
时间窗: baseline, week 4 (during treatment), week 24 (after end of treatment)
serum cholesterol, High density lipoproteins, Low density lipoproteins, Triglycerides, very low density lipoprotein , all measured in mg/dL after 12 hours of fasting
次要结局
- Treatment Response(12 WEEKS after end of therapy)
研究者
Nehal Khaled Abdel Raouf Abdel Fattah
Principal Investigator
Ain Shams University